Publication of Change in the Total Number of Shares and Votes in Diamyd

STOCKHOLM, Sweden, Nov. 30, 2009 (GLOBE NEWSWIRE) -- As of November 30, 2009, the share capital in Diamyd Medical AB (publ) is 14 313 563 SEK. The total number of votes is 2 078 400,5 and the total number of shares is 14 313 563, divided among 718 938 shares of series A (1 vote) and 13 594 625 shares of series B (1/10 vote).

This change is due to the rights issue resolved by the Board of Directors on September 15, 2009, which the extra shareholders' meeting approved accordingly on October 7, 2009. The rights issue has been registered at the Swedish Companies Registration Office and Euroclear Sweden AB in November 2009.

About Diamyd Medical

Diamyd Medical is a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications.The company's most advanced project is the GAD-based drug Diamyd(R) for type 1diabetes. Phase III trials for this drug are in progress in both Europe and the U.S. In addition, the company has initiated clinical studies in the U.S. in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS).The company has also out-licensed the use of GAD for the treatment of Parkinson's disease. The company currently has three clinical-phase products.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the U.S. (ticker: DMYDY)administered by the Pink OTC Markets and the Bank of New York Mellon (PAL).Further information is available on the company's website: www.diamyd.com.

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.